Overview

• The prosthesis is fashioned from the patient’s own pericardial tissue and mounted on a resorbable stent for catheter-based implantation.
• First two recipients were discharged within five days and resumed work within four weeks without open-heart surgery.
• EU has committed over eight million euros to support ongoing trials and expand the technology to other heart valves.
• Planned studies will assess long-term safety and growth compatibility in larger adult and pediatric cohorts.
• The resorbable stent is designed to dissolve over time, leaving a living valve that adapts and regenerates with the patient’s heart.